Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andreas Hochhaus, MD Prof Dr
Mannheim der Universitat Heidelberg
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
32 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Teva Investigational Site 013
Montreal, Canada
- Teva Investigational Site 009
Toronto, Canada
- Teva Investigational Site 029
Bordeaux, France
- Teva Investigational Site 021
Le Chesnay, France
- Teva Investigational Site 022
Lille, France
- Teva Investigational Site 020
Lyon, France
- Teva Investigational Site 024
Nice, France
- Teva Investigational Site 028
Paris, France
- Teva Investigational Site 023
Poitiers, France
- Teva Investigational Site 027
Strasbourg, France
- Teva Investigational Site 025
Toulouse, France
- Teva Investigational Site 026
Vandœuvre-lès-Nancy, France
- Teva Investigational Site 031
Berlin, Germany
- Teva Investigational Site 030
Mannheim, Germany
- Teva Investigational Site 050
Budapest, Hungary
- Teva Investigational Site 071
Hyderabad, India
- Teva Investigational Site 070
Mumbai, India
- Teva Investigational Site 090
Bologna, Italy
- Teva Investigational Site 060
Gdansk, Poland
- Teva Investigational Site 061
Warsaw, Poland
- Teva Investigational Site 080
Singapore, Singapore
- Teva Investigational Site 040
London, United Kingdom
- Teva Investigational Site 003
Los Angeles, California, United States
- Teva Investigational Site 007
Jacksonville, Florida, United States
- Teva Investigational Site 006
Atlanta, Georgia, United States
- Teva Investigational Site 008
Beech Grove, Indiana, United States
- Teva Investigational Site 011
Baltimore, Maryland, United States
- Teva Investigational Site 004
Boston, Massachusetts, United States
- Teva Investigational Site 005
Buffalo, New York, United States
- Teva Investigational Site 002
The Bronx, New York, United States
- Teva Investigational Site 010
Philadelphia, Pennsylvania, United States
- Teva Investigational Site 001
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 Sept 2006
- Primary completion
- 23 Mar 2010
- Completion
- 28 Jun 2013
- Last update posted
- 15 Nov 2021
- Registered enrollment
- 103
- Registry id
- NCT00375219
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.